1. Home
  2. AYTU vs XIN Comparison

AYTU vs XIN Comparison

Compare AYTU & XIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • XIN
  • Stock Information
  • Founded
  • AYTU N/A
  • XIN 1997
  • Country
  • AYTU United States
  • XIN China
  • Employees
  • AYTU N/A
  • XIN N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • XIN Homebuilding
  • Sector
  • AYTU Health Care
  • XIN Consumer Discretionary
  • Exchange
  • AYTU Nasdaq
  • XIN Nasdaq
  • Market Cap
  • AYTU 9.8M
  • XIN 15.9M
  • IPO Year
  • AYTU N/A
  • XIN N/A
  • Fundamental
  • Price
  • AYTU $1.38
  • XIN $2.27
  • Analyst Decision
  • AYTU
  • XIN
  • Analyst Count
  • AYTU 0
  • XIN 0
  • Target Price
  • AYTU N/A
  • XIN N/A
  • AVG Volume (30 Days)
  • AYTU 37.2K
  • XIN 27.5K
  • Earning Date
  • AYTU 02-12-2025
  • XIN 01-01-0001
  • Dividend Yield
  • AYTU N/A
  • XIN N/A
  • EPS Growth
  • AYTU N/A
  • XIN N/A
  • EPS
  • AYTU N/A
  • XIN N/A
  • Revenue
  • AYTU $79,759,000.00
  • XIN $667,143,185.00
  • Revenue This Year
  • AYTU N/A
  • XIN N/A
  • Revenue Next Year
  • AYTU N/A
  • XIN N/A
  • P/E Ratio
  • AYTU N/A
  • XIN $0.25
  • Revenue Growth
  • AYTU N/A
  • XIN N/A
  • 52 Week Low
  • AYTU $1.30
  • XIN $1.92
  • 52 Week High
  • AYTU $3.45
  • XIN $7.05
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 33.90
  • XIN 27.87
  • Support Level
  • AYTU $1.30
  • XIN $2.44
  • Resistance Level
  • AYTU $1.47
  • XIN $2.65
  • Average True Range (ATR)
  • AYTU 0.12
  • XIN 0.25
  • MACD
  • AYTU -0.01
  • XIN -0.04
  • Stochastic Oscillator
  • AYTU 17.78
  • XIN 1.83

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About XIN Xinyuan Real Estate Co Ltd

Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.

Share on Social Networks: